17
Feb

More patients with early-stage breast cancer may be able to avoid chemotherapy in the future

For women with intermediate risk recurrence score from 21-gene expression assay, less may be more

Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds.

The encouraging research, published in the journal CANCER, still needs to be validated in an ongoing international trial. If verified, women with intermediate scores may one day be able to avoid chemotherapy as standard of care.

Read Full Article Here >>